Hernandez-Ilizaliturri FJ - Search Results

1

Immunomodulatory drug CC-5013 or CC-4047 and rituximab enhance antitumor activity in a severe combined immunodeficient mouse lymphoma model.

Hernandez-Ilizaliturri FJ, Reddy N, Holkova B, Ottman E, Czuczman MS. Hernandez-Ilizaliturri FJ, et al. Clin Cancer Res. 2005 Aug 15;11(16):5984-92. doi: 10.1158/1078-0432.CCR-05-0577. Clin Cancer Res. 2005. PMID: 16115943

2

Neutrophils contribute to the biological antitumor activity of rituximab in a non-Hodgkin's lymphoma severe combined immunodeficiency mouse model.

Hernandez-Ilizaliturri FJ, Jupudy V, Ostberg J, Oflazoglu E, Huberman A, Repasky E, Czuczman MS. Hernandez-Ilizaliturri FJ, et al. Clin Cancer Res. 2003 Dec 1;9(16 Pt 1):5866-73. Clin Cancer Res. 2003. PMID: 14676108

3

Pro-apoptotic therapy with the oligonucleotide Genasense (oblimersen sodium) targeting Bcl-2 protein expression enhances the biological anti-tumour activity of rituximab.

Ramanarayanan J, Hernandez-Ilizaliturri FJ, Chanan-Khan A, Czuczman MS. Ramanarayanan J, et al. Br J Haematol. 2004 Dec;127(5):519-30. doi: 10.1111/j.1365-2141.2004.05239.x. Br J Haematol. 2004. PMID: 15566355 Free article.

4

Rituximab in combination with fludarabine chemotherapy in low-grade or follicular lymphoma.

Czuczman MS, Koryzna A, Mohr A, Stewart C, Donohue K, Blumenson L, Bernstein ZP, McCarthy P, Alam A, Hernandez-Ilizaliturri F, Skipper M, Brown K, Chanan-Khan A, Klippenstein D, Loud P, Rock MK, Benyunes M, Grillo-Lopez A, Bernstein SH. Czuczman MS, et al. J Clin Oncol. 2005 Feb 1;23(4):694-704. doi: 10.1200/JCO.2005.02.172. J Clin Oncol. 2005. PMID: 15681517 Clinical Trial.

5

Development of targeted therapies for B-cell non-Hodgkin lymphoma and multiple myeloma.

Hernandez-Ilizaliturri FJ, Gowda A, Czuczman MS. Hernandez-Ilizaliturri FJ, et al. Clin Adv Hematol Oncol. 2004 Sep;2(9):606-18. Clin Adv Hematol Oncol. 2004. PMID: 16163245 Review.

6

Concurrent administration of granulocyte colony-stimulating factor or granulocyte-monocyte colony-stimulating factor enhances the biological activity of rituximab in a severe combined immunodeficiency mouse lymphoma model.

Hernandez-Ilizaliturri FJ, Jupudy V, Reising S, Repasky EA, Czuczman MS. Hernandez-Ilizaliturri FJ, et al. Leuk Lymphoma. 2005 Dec;46(12):1775-84. doi: 10.1080/17402520500182329. Leuk Lymphoma. 2005. PMID: 16263581

7

Clinical efficacy of lenalidomide in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase II study.

Chanan-Khan A, Miller KC, Musial L, Lawrence D, Padmanabhan S, Takeshita K, Porter CW, Goodrich DW, Bernstein ZP, Wallace P, Spaner D, Mohr A, Byrne C, Hernandez-Ilizaliturri F, Chrystal C, Starostik P, Czuczman MS. Chanan-Khan A, et al. J Clin Oncol. 2006 Dec 1;24(34):5343-9. doi: 10.1200/JCO.2005.05.0401. Epub 2006 Nov 6. J Clin Oncol. 2006. PMID: 17088571 Clinical Trial.

8

Augmented antitumor activity against B-cell lymphoma by a combination of monoclonal antibodies targeting TRAIL-R1 and CD20.

Maddipatla S, Hernandez-Ilizaliturri FJ, Knight J, Czuczman MS. Maddipatla S, et al. Clin Cancer Res. 2007 Aug 1;13(15 Pt 1):4556-64. doi: 10.1158/1078-0432.CCR-07-0680. Clin Cancer Res. 2007. PMID: 17671142

9

Immunomodulatory drugs stimulate natural killer-cell function, alter cytokine production by dendritic cells, and inhibit angiogenesis enhancing the anti-tumour activity of rituximab in vivo.

Reddy N, Hernandez-Ilizaliturri FJ, Deeb G, Roth M, Vaughn M, Knight J, Wallace P, Czuczman MS. Reddy N, et al. Br J Haematol. 2008 Jan;140(1):36-45. doi: 10.1111/j.1365-2141.2007.06841.x. Epub 2007 Nov 9. Br J Haematol. 2008. PMID: 17995965 Free article.

10

CD52 over-expression affects rituximab-associated complement-mediated cytotoxicity but not antibody-dependent cellular cytotoxicity: preclinical evidence that targeting CD52 with alemtuzumab may reverse acquired resistance to rituximab in non-Hodgkin lymphoma.

Cruz RI, Hernandez-Ilizaliturri FJ, Olejniczak S, Deeb G, Knight J, Wallace P, Thurberg BL, Kennedy W, Czuczman MS. Cruz RI, et al. Leuk Lymphoma. 2007 Dec;48(12):2424-36. doi: 10.1080/10428190701647879. Leuk Lymphoma. 2007. PMID: 18067019

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

129 results

Search Page

Filters